Holen Sie sich die Stockscreener-App
5.10
2.20%
0.11
Candel Therapeutics Inc Aktie (CADL) Neueste Nachrichten
Candel Therapeutics Elects New Directors at Annual Meeting - TipRanks
Candel Therapeutics, Inc.'s (NASDAQ:CADL) latest 15% decline adds to one-year losses, institutional investors may consider drastic measures - simplywall.st
Candel Therapeutics, Inc. (NASDAQ:CADL) Shares Purchased by Squarepoint Ops LLC - Defense World
Candel Therapeutics appoints new board member ahead of BLA submission By Investing.com - Investing.com South Africa
Small cap wrap: HIVE Digital, TNR Gold, Candel Therapeutics... - Proactive financial news
Candel Therapeutics Appoints Maha Radhakrishnan, M.D., To Board - citybiz
Candel Therapeutics, Inc. Appoints Maha Radhakrishnan to Its Board of Directors - marketscreener.com
Candel Therapeutics adds biotech veteran Maha Radhakrishnan to Board - Proactive financial news
Candel Therapeutics appoints new board member ahead of BLA submission - Investing.com
Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors - GlobeNewswire
Former Biogen Chief Medical Officer Joins Candel Board as Prostate Cancer Drug Nears FDA Filing - Stock Titan
Candel Therapeutics, Inc. (NASDAQ:CADL) Shares Bought by Nuveen Asset Management LLC - Defense World
BNP Paribas Financial Markets Takes Position in Candel Therapeutics, Inc. (NASDAQ:CADL) - Defense World
Does Candel Therapeutics (CADL) Have the Potential to Rally 285.32% as Wall Street Analysts Expect? - MSN
CADL to Present Phase 3 Prostate Cancer Trial Insights | CADL St - GuruFocus
CADL to Present Phase 3 Prostate Cancer Trial Insights | CADL Stock News - GuruFocus
Deutsche Bank AG Boosts Stake in Candel Therapeutics, Inc. (NASDAQ:CADL) - Defense World
Candel Therapeutics, Inc. (CADL)’s CAN-2409 Advances with FDA RMAT Status for Localized Prostate Cancer - MSN
CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer - sharewise
Candel Therapeutics (CADL) Gains on FDA RMAT Designation for CAN-2409 - GuruFocus
Candel Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:CADL - Benzinga
Candel Therapeutics gains FDA RMAT status for prostate cancer therapy By Investing.com - Investing.com South Africa
(CADL) Trading Report - news.stocktradersdaily.com
Candel Therapeutics Stock Soars On FDA’s RMAT Designation For Prostate Cancer Therapy: Retail Considers It Good Long-Term Buy By Stocktwits - Investing.com India
Small cap wrap: Midnight Sun Mining, MustGrow Biologics, Candel Therapeutics, HIVE... - Proactive financial news
Market movers: GameStop, Okta, Abercrombie, Candel Therapeutics... - Proactive financial news
Candel Says FDA Grants Regenerative Medicine Advanced Therapy Designation to Prostate Cancer Drug - marketscreener.com
Candel stock gains after FDA RMT designation (CADL:NASDAQ) - Seeking Alpha
Candel Therapeutics Stock Soars On FDA’s RMAT Designation For Prostate Cancer Therapy: Retail Considers It Good Long-Term Buy - MSN
Candel Therapeutics (CADL) Stock Is Surging Wednesday: What's Going On? - Benzinga
Candel Therapeutics get FDA’s RMAT designation for prostate cancer therapy - Proactive financial news
Candel Therapeutics gains FDA RMAT status for prostate cancer therapy - Investing.com Australia
Candel Therapeutics (CADL) Receives RMAT Designation for CAN-2409 in Prostate Cancer | CADL Stock News - GuruFocus
Candel Therapeutics Receives FDA RMAT Designation for CAN-2409 - TipRanks
Candel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate Cancer - The Manila Times
Candel Therapeutics Receives FDA Regenerative Medicine - GlobeNewswire
Breakthrough: FDA Fast-Tracks Revolutionary Prostate Cancer Therapy Showing 80% Complete Response Rate - Stock Titan
Northern Trust Corp Purchases 6,250 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) - Defense World
Candel Therapeutics (CADL) to Reveal Positive Phase 3 Results fo - GuruFocus
Candel Therapeutics (CADL) to Reveal Positive Phase 3 Results for Prostate Cancer | CADL Stock News - GuruFocus
Candel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation - The Manila Times
Candel Therapeutics to Host Investor Conference Call - GlobeNewswire
Candel Therapeutics to host June 3 call on positive Phase 3 results for prostate cancer therapy - Proactive financial news
Wall Street Analysts Predict a 310.96% Upside in Candel Therapeutics (CADL): Here's What You Should Know - MSN
Candel Therapeutics: CAN-2409’s Promising Progress Deserves An Upgrade (NASDAQ:CADL) - Seeking Alpha
Candel Therapeutics, Inc. (CADL) to Present Positive Phase 3 Prostate Cancer Data at ASCO 2025 - MSN
Candel Therapeutics (NASDAQ:CADL) Upgraded at Wall Street Zen - Defense World
Small cap wrap: Excellon Resources, Candel Therapeutics, Forte Minerals... - Proactive financial news
Candel Therapeutics to present Phase 3 prostate cancer trial data at ASCO 2025 - Proactive financial news
Candel’s phase 3 trial for prostate cancer therapy shows promise By Investing.com - Investing.com Nigeria
Candel Therapeutics Unveils Promising Phase 3 Trial Results - TipRanks
Candel Therapeutics to Present Positive Phase 3 Clinical Trial Results of CAN-2409 for Prostate Cancer at ASCO 2025 - Nasdaq
Candel Therapeutics Presents Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025 - GlobeNewswire
0.68%
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):